Kinarus Therapeutics (SIX: KNRS)

Currency in CHF

Last close As at 28/03/2023

CHF0.01

0.00 (−8.33%)

Market capitalisation

CHF15m

Based in Switzerland, Kinarus Therapeutics is a clinical-stage pharmaceutical company focused on advancing lead candidate KIN001 in inflammatory, fibrotic and/or viral infection-related conditions.

Upon availability of new funding, Kinarus plans to start a Phase II study in wet AMD, backed by preclinical data suggesting potential benefit in reducing choroidal neovascularisation lesions, and in IPF. Having shown in vitro antiviral activity against many COVID-19 variants, KIN001 is currently being assessed in the KINFAST Phase II study in ambulatory COVID-19 patients.

Sector

Healthcare

Equity Analyst

Pooya Hemami

Analyst - Healthcare

Key Management

  • Dr. Alexander Bausch

    CEO

  • Subhasis Roy

    CFO

Balance Sheet

Forecast net debt (CHFm)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (29.3) (10.2) (84.6)
Relative (26.5) (9.7) (82.7)
52 week high/low CHF0.1/CHF0.0

Financials

Kinarus Therapeutics is advancing KIN001, a patented orally dosed combination of p38 mitogen-activated protein kinase inhibitor pamapimod and pioglitazone. Preclinical data suggest this combination may have anti-inflammatory and anti-fibrotic activity, as well as antiviral properties against COVID-19. KIN001 is under development for the treatment of wet age-related macular degeneration (wet AMD), its lead indication, as well as idiopathic pulmonary fibrosis (IPF) and COVID-19. Wet AMD is a leading cause of vision loss in older adults and there are no oral drugs approved to treat the condition, signalling a potentially significant unmet need.

Y/E Dec Revenue (CHFm) EBITDA (CHFm) PBT (CHFm) EPS (fd) (CHFc) P/E (x) P/CF (x)
2020A 0.0 (1.5) (1.5) (31.17) N/A N/A
2021A 0.0 (5.1) (4.9) (0.41) N/A N/A
2022E N/A N/A N/A N/A N/A N/A
2023E N/A N/A N/A N/A N/A N/A

Research

Healthcare

Drug delivery platforms

Healthcare

Neuroscience comeback

Consumer

IPO apocalypse

TMT

ESG, moving beyond the box tick

Healthcare

Artificial intelligence in drug discovery

Healthcare

Edison Exhibits- antibiotic development

Healthcare

The next wave in AMD

Healthcare

Cannabinoid Therapies- The coming retail wave

Healthcare

The diagnostics sector

Healthcare

ASCO 2017